IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Should You Buy?

Shares of IPSEN (OTCMKTS:IPSEY) gapped up before the market opened on Wednesday . The stock had previously closed at $44.07, but opened at $47.11. IPSEN shares last traded at $47.11, with a volume of 2,108 shares.

Analysts Set New Price Targets

A number of analysts have weighed in on IPSEY shares. HC Wainwright reissued a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Finally, Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

IPSEN Stock Up 6.9%

The company’s fifty day simple moving average is $46.35 and its 200-day simple moving average is $45.00.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).